Pfizer struck a broad oncology collaboration with Innovent Biologics to develop 12 antibody-drug conjugates and multispecific antibody programs, anchored by early-stage discovery from Innovent and global development handoffs after Phase 1. The deal includes $650 million upfront and up to $9.85 billion in potential milestones plus royalties, with Innovent leading Phase 1 and Pfizer taking over later globally. The portfolio structure splits responsibilities across multiple programs: Innovent provides eight early-stage options while Pfizer contributes four discovery programs, with cost sharing for selected assets through clinical development. The agreement widens the playbook for multinational licensing into China’s de novo antibody pipeline, reinforcing the centrality of ADCs and multispecifics in near-term oncology growth. Separately, reporting on the same partnership emphasized the size of Pfizer’s commitment and the expectation that it will help Innovent advance candidates through Phase I before Pfizer assumes broader development globally. Market participants are likely to watch subsequent program selections and early clinical updates as milestones approach. For biotech teams, the deal’s speed-to-Phase-1 structure signals continued preference for platforms that can quickly generate clinical-stage candidates, while also highlighting how large companies are reorganizing portfolios around targeted modalities rather than solely small molecules.